DOA0 Stock Overview
A late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Soligenix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.19 |
| 52 Week High | US$3.91 |
| 52 Week Low | US$2.19 |
| Beta | 1.93 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| DOA0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -16.7% | 1.2% | 0.8% |
| 1Y | n/a | -16.0% | 6.1% |
Return vs Industry: Insufficient data to determine how DOA0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how DOA0 performed against the German Market.
Price Volatility
| DOA0 volatility | |
|---|---|
| DOA0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: DOA0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine DOA0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 14 | Christopher Schaber | www.soligenix.com |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet’s Disease.
Soligenix, Inc. Fundamentals Summary
| DOA0 fundamental statistics | |
|---|---|
| Market cap | €2.06m |
| Earnings (TTM) | -€6.48m |
| Revenue (TTM) | €646.63k |
3.2x
P/S Ratio-0.3x
P/E RatioIs DOA0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DOA0 income statement (TTM) | |
|---|---|
| Revenue | US$699.21k |
| Cost of Revenue | US$633.04k |
| Gross Profit | US$66.17k |
| Other Expenses | US$7.08m |
| Earnings | -US$7.01m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.10 |
| Gross Margin | 9.46% |
| Net Profit Margin | -1,002.55% |
| Debt/Equity Ratio | 389.9% |
How did DOA0 perform over the long term?
See historical performance and comparison